UnitedHealth, FTC Near Settlement on Insulin Rebates

By Healthcare Technology News · June 13, 2026

UnitedHealth Group and the Federal Trade Commission reached a tentative agreement as of June 12 to resolve allegations that the company's pharmacy benefit operations inflated insulin prices, according to Becker's Hospital Review. The settlement would cover Optum Rx, UnitedHealth's PBM, and its group purchasing organization, Emisar Pharma Services.

The FTC sued in 2024, arguing the country's three largest PBMs and their affiliated drug-buying groups had "created a broken rebate system that inflated insulin drug prices." The agency's core claim is that PBMs steered patients toward higher-priced insulins because those drugs generated larger rebates, leaving some patients paying more at the pharmacy counter. Optum Rx and Emisar were one of three sets of defendants named in the complaint.

A settlement with UnitedHealth would mark a notable step in the FTC's broader scrutiny of PBM pricing practices. It also signals how regulators intend to police the rebate-driven middle of the drug supply chain, a structure long criticized for obscuring true drug costs from patients and employers.

Judge Sends Ballad Health's UnitedHealth MA Suit to Arbitration

A federal judge dismissed Ballad Health's Medicare Advantage lawsuit against UnitedHealth, ordering the payment dispute into arbitration.

Why it matters: Arbitration clauses in payer contracts can quietly steer provider-insurer disputes out of court, shaping how health systems fight Medicare Advantage denials.

September 15, 2026

Payers

Medicare Advantage Plans Rethink Post-Discharge Care Transitions

Medicare Advantage plans are refocusing on the post-discharge period to reduce readmissions and protect Star Ratings.

Why it matters: Star Ratings drive billions in bonus payments and enrollment, and better care transitions are becoming a key way plans defend those scores.

September 8, 2026

Payers

Vertical Integration Is Quietly Inflating Patient Bills

KFF Health News details how vertical integration across hospitals, insurers, and pharmacies steers patients toward higher-priced care and inflates their bills.

Why it matters: As a handful of integrated companies control care, coverage, and drugs, patients face higher costs with little visibility into why.